- Home
- ATOS vs RCEL Comparison
ATOS vs RCEL Comparison
Compare ATOS & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- RCEL
- Stock Information
- Founded
- ATOS 2009
- RCEL N/A
- Country
- ATOS United States
- RCEL United States
- Employees
- ATOS N/A
- RCEL N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- ATOS Health Care
- RCEL Health Care
- Exchange
- ATOS Nasdaq
- RCEL Nasdaq
- Market Cap
- ATOS 107.2M
- RCEL 113.7M
- IPO Year
- ATOS 2012
- RCEL N/A
- Fundamental
- Price
- ATOS $0.84
- RCEL $4.56
- Analyst Decision
- ATOS Strong Buy
- RCEL Strong Buy
- Analyst Count
- ATOS 3
- RCEL 4
- Target Price
- ATOS $6.17
- RCEL $13.75
- AVG Volume (30 Days)
- ATOS 483.0K
- RCEL 286.8K
- Earning Date
- ATOS 11-11-2025
- RCEL 11-06-2025
- Dividend Yield
- ATOS N/A
- RCEL N/A
- EPS Growth
- ATOS N/A
- RCEL N/A
- EPS
- ATOS N/A
- RCEL N/A
- Revenue
- ATOS N/A
- RCEL $74,884,000.00
- Revenue This Year
- ATOS N/A
- RCEL $28.23
- Revenue Next Year
- ATOS N/A
- RCEL $35.24
- P/E Ratio
- ATOS N/A
- RCEL N/A
- Revenue Growth
- ATOS N/A
- RCEL 38.32
- 52 Week Low
- ATOS $0.55
- RCEL $3.60
- 52 Week High
- ATOS $1.66
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- ATOS 60.84
- RCEL 46.58
- Support Level
- ATOS $0.81
- RCEL $4.12
- Resistance Level
- ATOS $0.80
- RCEL $4.44
- Average True Range (ATR)
- ATOS 0.03
- RCEL 0.25
- MACD
- ATOS 0.01
- RCEL 0.03
- Stochastic Oscillator
- ATOS 92.67
- RCEL 50.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.